Ad
related to: acadia pharmaceuticals rumors update- Find A Donation Center
Find the nearest plasma center
Come visit us today
- Why We Compensate
We recognize your time is valuable
We appreciate your commitment
- Plasma FAQ
Get answers to common questions
A collection of frequent questions
- Reasons To Donate
Help someone breathe easier
Dedicated to improving lives
- Find A Donation Center
Search results
Results From The WOW.Com Content Network
Shares of the California-based company fell 16% in extended trading. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the ...
Acadia's drug, trofinetide, to treat Rett syndrome, a genetic brain disorder, was launched in the U.S. last year under the brand name Daybue. "Acadia has misrepresented Daybue's safety profile ...
Has Wall Street gone a bit overboard punishing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? The drug maker’s share price continues to fall Wednesday on the heels of a disappointing 4Q earnings ...
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold ...
Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009. [ 5 ] [ 6 ] [ 7 ] Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia -related psychosis, [ 8 ] major depressive disorder , [ 9 ] schizophrenia ...
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.
For premium support please call: 800-290-4726 more ways to reach us
The stock of ACADIA Pharmaceuticals (NAS:ACAD, 30-year Financials) appears to be possible value trap, according to GuruFocus Value calculation.